February 18, 2015
PET/CT scans changed treatment in more than 28% of patients
Reston, Va. (February 18, 2015) – New research from Johns Hopkins School of Medicine reveals a high value of scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer. The study, featured in the February 2015 issue of The Journal of Nuclear Medicine, establishes the value of fourth and subsequent follow-up PET/CT scans in clinical assessment and management change in patients with the disease.
According to the American Lung Association, lung cancer is the leading cancer killer in both men and women in the United States. Approximately 402,326 Americans living today have been diagnosed with lung cancer. In 2014, diagnoses of an estimated 224,210 new cases of lung cancer were expected, representing about 13 percent of all cancer diagnoses.
In the retrospective study, a total of 1,171 patients with biopsy-proven lung cancer who had positron emission tomography with a radioactive tracer (18F-FDG were identified at a single tertiary center from 2001 to 2013. Among these, 85 patients (7.3%) had four or more follow up PET/CT scans with a total of 285 fourth and subsequent follow up PET/CT scans. Median follow up from the fourth scan was 31.4 months. The follow-up PET/CT scan results were correlated with clinical assessment and treatment changes.
Of the 285 fourth and subsequent follow-up PET/CT scans, 149 (52.28%) were interpreted as positive and 136 (47.7%) were interpreted as negative for recurrence or metastasis. A total of 47 (55.3%) patients died during the study period. PET/CT identified recurrence or metastasis in 44.3% of scans performed without prior clinical suspicion and ruled out recurrence or metastasis in 24.2% of scans performed without prior clinical suspicion. The PET/CT scan resulted in treatment change in 28.1% (80/285) of the patients. New treatment was initiated in 20.4% (58/285) scan times, treatment was changed in 5.6% (16/285) scan times and ongoing treatment was stopped in 2.1% (6/285) scan times.
“Although the value of FDG PET/CT has been established in the follow-up of patients with lung cancer, this study specifically looks at the value of the fourth and subsequent follow-up PET/CT studies, which has not been addressed in any prior studies,” states Rathan Subramaniam, MD, PhD, lead author of the study. “We now need to establish similar evidence for other human solid tumors,” Subramaniam continues.
The study was performed in the context of the recent Center for Medicaid and Medicare Services declaration that only three FDG PET/CT scans will be covered under section 1862(a)(1)(A) when used to guide subsequent management of anti-tumor treatment strategy after completion of initial anticancer therapy. Coverage of any additional FDG PET/CT scans will be determined by local Medicare administrative contractors.
Authors of the article “FDG PET/CT & Lung Cancer: Value of Fourth and Subsequent Post Therapy follow up scans for Patient Management” include Alexander Antoniou, Charles Marcus, Vasavi Paidpally, Rathan M. Subramaniam, Richard L. Wahl, and Atif Zaheer, Russell H. Morgan Department of Radiology and Radiological Sciences Johns Hopkins School of Medicine, Baltimore, MD.
Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Kimberly Brown at (703) 652-6773 or firstname.lastname@example.org. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s more than 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.